Daniel T. Scavilla - 04 Mar 2026 Form 4 Insider Report for DENTSPLY SIRONA Inc. (XRAY)

Role
President, CEO & Member of BOD, Director
Signature
/s/ Jessica Nielsen Causey, Attorney-in-Fact for Daniel T. Scavilla
Issuer symbol
XRAY
Transactions as of
04 Mar 2026
Net transactions value
$0
Form type
4
Filing time
06 Mar 2026, 17:25:07 UTC
Previous filing
26 Feb 2026
Next filing
12 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Scavilla Daniel T President, CEO & Member of BOD, Director C/O DENTSPLY SIRONA INC, 13320-B BALLANTYNE CORPORATE PLACE, CHARLOTTE /s/ Jessica Nielsen Causey, Attorney-in-Fact for Daniel T. Scavilla 06 Mar 2026 0001642439

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XRAY Common Stock Award +145,089 +866% $0.000000* 161,839 04 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XRAY Stock Option (Right to Buy) Award +2,066,600 $0.000000* 2,066,600 04 Mar 2026 Common Stock 2,066,600 $15.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029.
F2 Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 115% of the closing price of the Issuer's common stock as of the date of grant.